1. Biochemical and chemotherapeutic studies on 2, 4-diamino -6/2,5 dimethoxybenzyl/5-methylpyrido /2,3-d/pyrimidine/BW 301 U/, a novel lipidsoluble inhibitor of dihydrofolate reductase;Duch;Cancer Res,1982
2. Metabolic inhibition by a new antifolate 2,4-diamino-6/2,5-dimethoxybenzyl/-5-methylpyrido / 2,3-d/pyrimidine /BW 301 U/, an effective inhibitor of human lymphoid and dihydrofolate reductase over producing mouse cell lines;Sedwick;Mol Pharmacol,1982
3. A phase I clinical and pharmacological study of weekly intravenous infusions of Piritrexim /BW 301 U/;Weiss;Eur J Cancer Clin Oncol,1989
4. Phase I trial of Piritrexim capsules using prolonged low-dose oral administration for the treatment of advanced malignancies;Feun;J Natl Cancer Inst,1991
5. Pediatric phase I trial, pharmacokinetic study and limited sampling strategy for Piritrexim administered on a low-dose, intermittent schedule;Adamson;Cancer Res,1992